A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC) Meeting Abstract
| Authors: | Beltran, H.; Danila, D.; Montgomery, B.; Szmulewitz, R.; Vaishampayan, U.; Armstrong, A.; Stein, M.; Hoimes, C.; Pinski, J.; Scher, H.; Puca, L.; Bareja, R.; Wong, W.; Rubin, M.; Mosquera, J. M.; Sboner, A.; Oromendia, C.; Nanus, D.; Ballman, K.; Tagawa, S. T. |
| Abstract Title: | A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC) |
| Meeting Title: | 41st European Society for Medical Oncology Congress (ESMO) |
| Journal Title: | Annals of Oncology |
| Volume: | 27 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2016 Oct 7-11 |
| Meeting Location: | Copenhagen, Denmark |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2016-10-01 |
| Start Page: | vi565 |
| Language: | English |
| ACCESSION: | WOS:000393913000710 |
| DOI: | 10.1093/annonc/mdw435.21 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA29 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
